Qualigen Corp (QLGN) - יתרות מזומנים בחישוב למניה

The prospects for Qualigen Therapeutics (QLGN) depend on patent monetization and the pursuit of M&A deals to advance viral therapies. An analysis of cash per share confirms liquidity trends, where the 7.55 mark indicates the current state of reserves. Qualigen Therapeutics (QLGN) utilizes nanotechnology for drug delivery, which allows the company to maintain significant pricing power. However, the aging FastPack platform is seeing declining returns, failing to cover biotech sector expenses.
פילוחים אנליטיים של חברת Qualigen Therapeutics, Inc. (QLGN)

A fundamental liquidity assessment determines a business's resilience to operational risks. This indicator measures the volume of available cash per common share. Analyzing the cash per share with a current value of 7.55 allows for tracking the dynamics of the financial cushion. For the pre-revenue biotech Qualigen Therapeutics (QLGN), this is a critical survival marker. A decline in this metric directly signals the approach of another round of equity dilution.